Bristol-Myers Squibb - Belatacept (Nulojix) Approval comes with black box warning - Our discussion with Key Opinion Leader indicates slow ramp up
FDA has granted approval to belatacept (Nulojix) as prophylaxis of organ rejection use in EBV seropositive adult kidney transplant patients (comprising ~85-90% kidney transplant patients). The label also includes a black box warning on risk of PTLD (post transplant lymphoproliferative disorder), infection/malignancies and prohibits use in liver transplant patients. The approval is in line with our expectations and based on our discussion with KOL, we expect a slow ramp-up with peak sales potential of $700m. Our discussion with KOL suggests Belatacept to be used as rescue therapy in patients facing CNI based nephrotoxicity……….
COMPANIES MENTIONED
Bristol-Myers Squibb, BMY
Bristol-Myers Squibb, BMY
